Listed

Kailera Therapeutics, Inc.

KLRANasdaqCIK 2096997HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$121.4m, Q2 FY2026
Net income−$111.3m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m10.1Research and development, period not labelled, three months to 2025-03-31$10.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure19.5Research and development, period not labelled, three months to 2025-06-30$19.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure70.9Research and development, Q1 FY2026, three months to 2026-03-31$70.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure101Research and development, Q2 FY2026, three months to 2026-06-30$101.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Operating income$m(20.5)Operating income, period not labelled, three months to 2025-03-31−$20.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(30.7)Operating income, period not labelled, three months to 2025-06-30−$30.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(84.7)Operating income, Q1 FY2026, three months to 2026-03-31−$84.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(121)Operating income, Q2 FY2026, three months to 2026-06-30−$121.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Net income$m(18.0)Net income, period not labelled, three months to 2025-03-31−$18.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(28.9)Net income, period not labelled, three months to 2025-06-30−$28.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(78.9)Net income, Q1 FY2026, three months to 2026-03-31−$78.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(111)Net income, Q2 FY2026, three months to 2026-06-30−$111.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Diluted EPS$ per share(17983.00)Diluted EPS, period not labelled, three months to 2025-03-31−$17983.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(28947.00)Diluted EPS, period not labelled, three months to 2025-06-30−$28947.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(3650.00)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$3650.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(1.09)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Basic EPS$ per share(17983.00)Basic EPS, period not labelled, three months to 2025-03-31−$17983.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(28947.00)Basic EPS, period not labelled, three months to 2025-06-30−$28947.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(3650.00)Basic EPS, Q1 FY2026, three months to 2026-03-31−$3650.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(1.09)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure

Balance sheet

Cash and equivalents$130.3m, Q2 FY2026
Shareholders' equity$1.12bn, Q2 FY2026
Line itemUnitperiod not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30period not labelled2025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported102Cash and equivalents, period not labelled, at 2025-03-31$101.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure101Cash and equivalents, period not labelled, at 2025-06-30$101.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure160Cash and equivalents, period not labelled, at 2025-12-31$160.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure112Cash and equivalents, Q1 FY2026, at 2026-03-31$111.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure130Cash and equivalents, Q2 FY2026, at 2026-06-30$130.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Current assets$mnot reportednot reportednot reported558Current assets, period not labelled, at 2025-12-31$557.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure530Current assets, Q1 FY2026, at 2026-03-31$530.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure929Current assets, Q2 FY2026, at 2026-06-30$929.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Total assets$mnot reportednot reportednot reported692Total assets, period not labelled, at 2025-12-31$692.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure625Total assets, Q1 FY2026, at 2026-03-31$624.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure1,211Total assets, Q2 FY2026, at 2026-06-30$1.21bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Current liabilities$mnot reportednot reportednot reported46.4Current liabilities, period not labelled, at 2025-12-31$46.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure54.8Current liabilities, Q1 FY2026, at 2026-03-31$54.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure83.7Current liabilities, Q2 FY2026, at 2026-06-30$83.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Total liabilities$mnot reportednot reportednot reported56.4Total liabilities, period not labelled, at 2025-12-31$56.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure64.5Total liabilities, Q1 FY2026, at 2026-03-31$64.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure93.0Total liabilities, Q2 FY2026, at 2026-06-30$93.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure
Shareholders' equity$m(219)Shareholders' equity, period not labelled, at 2024-12-31−$218.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(235)Shareholders' equity, period not labelled, at 2025-03-31−$235.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(263)Shareholders' equity, period not labelled, at 2025-06-30−$262.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(356)Shareholders' equity, period not labelled, at 2025-12-31−$356.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure(432)Shareholders' equity, Q1 FY2026, at 2026-03-31−$432.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure1,118Shareholders' equity, Q2 FY2026, at 2026-06-30$1.12bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure

Cash flow

Operating cash flow−$77.5m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(18.2)Operating cash flow, period not labelled, three months to 2025-03-31−$18.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(26.2)Operating cash flow, period not labelled, three months to 2025-06-30−$26.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-346958. Derived: 6-month figure less the 3-month figure.Report this figure(68.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$68.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure(77.5)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$77.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-346958. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)102.23m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.0Diluted shares (weighted), period not labelled, three months to 2025-03-311 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure0.0Diluted shares (weighted), period not labelled, three months to 2025-06-301 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure0.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3121,607 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-26, accession 0001193125-26-239417.Report this figure102Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30102,226,608 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure

Shares outstanding: 129.64mShares outstanding, period not labelled, at 2026-08-06129,643,676 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-12, accession 0001193125-26-346958.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.